What question did this study set out to answer?

The aim is to discuss recent advances in CAR-NK cell therapies and their potential applications.

April 22, 2026

CAR‐NK cell‐based therapies: translational and regulatory breakthroughs

ABAlison Felipe Bordini BiggiThe University of Queensland FSFernando Souza‐Fonseca‐Guimaraes

Key Points

The aim is to discuss recent advances in CAR-NK cell therapies and their potential applications.
Discuss advances in chimeric antigen receptor (CAR) technology for NK cells.
Highlight the role of iPSC-derived manufacturing in therapy development.
Explore intrinsic regulators and antigen targeting for broadened clinical use.
Demonstrated progress in CAR-NK therapies that may extend beyond cancer to autoimmune diseases.
Identified key advancements in manufacturing and regulatory approaches that enhance clinical applicability.

Abstract

In this article for the "Highlights of 2025" series, we discuss advances in chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapies. We highlight iPSC-derived manufacturing, expansion into autoimmune disease, discovery of intrinsic regulators, and rational antigen targeting, illustrating how discovery-driven biology and engineering are reshaping CAR-NK therapies toward broader clinical applicability. Figure made in ©BioRender-biorender.com.

AI से पूछें

Bookmark

View Full Paper